Please assess the completion status of the following clinical trial:

Trial Title: T Cells and TNF (Tumor Necrosis Factor): The Impact of TNF Blockade

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Only anti-TNF naïve patients will be included in this study~* Patients between 18 to 80 years of age~* Patients due to start treatment with anti-TNF blocking agents - etanercept or adalimumab~Patients with rheumatoid arthritis~* Only patients meeting the 1987 American College of Rheumatology (ACR) revised classification criteria for rheumatoid arthritis will be included~* Patients should have active rheumatoid arthritis, defined by an initial DAS28 score \>5.1~* Patients should have at least 1 joint suitable for synovial biopsy~* Patients can be on concurrent DMARDs but they should have been on a stable dose of DMARD for at least 1 month prior to study entry~* Patients can be on a concurrent dose of glucocorticoids (up to 10mg daily) and they should have been on a stable dose for at least 4 weeks prior to study entry~Patients with psoriatic arthritis~* Patients should have a secure diagnosis of psoriatic arthritis determined by a rheumatologist~* Patients with psoriatic arthritis included in this study should have evidence of concurrent psoriatic skin lesions at the time of study entry~* Patients should have at least one joint suitable for synovial biopsy~* Patients can be on concurrent DMARDs - they should be on a stable dose of DMARD for at least 1 month prior to study entry~Patients with Ankylosing spondylitis~* Patient should fulfil the Modified New York Criteria for diagnosis of ankylosing spondylitis~* Patients can be on concurrent NSAIDs~* Patients can be on concurrent DMARDs - they should be on a stable dose of DMARD for at least 1 month prior to study entry~Exclusion Criteria:~* Patients who have been previously treated with anti-TNF therapy for whatever reason~* Patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis who do not fulfil the diagnostic criteria for these conditions as above~* Patient who have received an intra-articular injection of steroids or have received an intra-muscular injection of depot steroid to treat disease flare in the preceding 4 weeks prior to commencing anti-TNF therapy.~* Patients with intercurrent, active infection of any type, excluding the common cold

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Rheumatoid arthritis (Type: None): Participants with Rheumatoid arthritis
- Ankylosing spondylitis (Type: None): Participants with Ankylosing spondylitis
- Psoriatic arthritis (Type: None): Participants with Psoriatic arthritis

Based on this trial design, predict the completion outcome and termination type (if applicable).